Research Article

Noncoding RNA Transcripts during Differentiation of Induced Pluripotent Stem Cells into Hepatocytes

Aniela Skrzypczyk,1 Stephanie Kehr,2 Ilona Krystel,1 Stephan H. Bernhart,2,3 Shibashish Giri,1,4 Augustinus Bader,1 and Peter F. Stadler2,5,6,7,8,9,10

1Applied Stem Cell Biology and Cell Technology, Biomedical and Biotechnological Center, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany
2Bioinformatics Group, Department of Computer Science, and Interdisciplinary Centre for Bioinformatics, Leipzig University, Härtelstr. 1618, 04107 Leipzig, Germany
3Transcriptome Bioinformatics Group at the Interdisciplinary Centre for Bioinformatics, Leipzig University, Härtelstr. 1618, 04107 Leipzig, Germany
4Department of Plastic Surgery and Hand Surgery, University Hospital Rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 Munich, Germany
5Competence Center for Scalable Data Services and Solutions Dresden/Leipzig, German Centre for Integrative Biodiversity Research (iDiv), and Leipzig Research Center for Civilization Diseases, Universität Leipzig, Ritterstrasse 9-13, 04109 Leipzig, Germany
6Max Planck Institute for Mathematics in the Sciences, Insel Strasse 22, 04103 Leipzig, Germany
7Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103 Leipzig, Germany
8Department of Theoretical Chemistry, University of Vienna, Wahringerstrasse 17, 1090 Vienna, Austria
9Center for RNA in Technology and Health, University of Copenhagen, Grønnegårdsvej 3, Frederiksberg C, Denmark
10Santa Fe Institute, 1399 Hyde Park Road, Santa Fe NM 87501, USA

Correspondence should be addressed to Shibashish Giri; shibashish.giri@bbz.uni-leipzig.de

Received 15 January 2018; Revised 20 May 2018; Accepted 12 June 2018; Published 19 August 2018

Academic Editor: Gerald A. Colvin

Copyright © 2018 Aniela Skrzypczyk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The publication of this article was funded by Max Planck.

Recent advances in the stem cell field allow to obtain many human tissues in vitro. However, hepatic differentiation of induced pluripotent stem cells (iPSCs) still remains challenging. Hepatocyte-like cells (HLCs) obtained after differentiation resemble more fetal liver hepatocytes. MicroRNAs (miRNA) play an important role in the differentiation process. Here, we analysed noncoding RNA profiles from the last stages of differentiation and compare them to hepatocytes. Our results show that HLCs maintain an epithelial character and express miRNA which can block hepatocyte maturation by inhibiting the epithelial-mesenchymal transition (EMT). Additionally, we identified differentially expressed small nucleolar RNAs (snoRNAs) and discovered novel noncoding RNA (ncRNA) genes.

1. Introduction

Human iPSC technology provides a powerful tool for both regenerative medicine and development analysis. Stem cells hold the potential to recapitulate embryonic differentiation of many tissues in vitro. Moreover, differentiated cells can replace damaged or degenerated cells in vivo (reviewed by [1, 2]). The liver is a complex organ with a high variety of functions. It is essential for detoxification and bile production. End-stage liver diseases are associated with hepatocyte apoptosis [3]. Currently, there is no possible compensation for liver failure. For many patients, the only option to survive is through liver transplant, which is limited due to organ shortage. iPSCs could potentially be the source of cells for
bioartificial liver devices or transplantsations [4]. To avoid tumorigenesis and ensure proper function, iPSCs must be fully differentiated. A variety of hepatic differentiation protocols has been described [5, 6]. However, the process of hepatic differentiation still needs to be improved. After differentiation, cells express several mature hepatic markers and functions, but it has been shown that they resemble fetal hepatocytes [7]. miRNAs are well-known regulators of gene expression during liver development [8]. These 21-22-nucleotide-long molecules can affect expression of multiple genes simultaneously by binding to complementary regions of messenger RNAs (mRNA). This interaction causes degradation or repression of the target transcript. miR-122 is the most abundant miRNA in the liver, and it has been shown that overexpression of miR-122 can enhance hepatic maturation of fetal liver progenitors [9]. Another important group of noncoding RNAs (ncRNAs) is the snoRNAs. They act as guides for chemical modifications in other RNAs, mainly in ribosomal RNA (rRNA). Based on different sequence motifs and secondary structures, snoRNAs are divided into two types: CD box snoRNAs, guiding ribose methylation, and H/ACA box snoRNAs which guide pseudouridylation [10, 11]. Some specific snoRNAs are known to also act in a miRNA-like fashion [12–14]. In human tissues, snoRNAs have been observed to be subject to differential expression [15] and have recently attracted attention as biomarkers [16–18].

In this study, we explore the involvement of miRNAs and snoRNAs in the dynamics of hepatic differentiation to shed light on the molecular and regulatory mechanisms that underlie this complex process. We compare miRNA expression profiles of HLCs at two stages of differentiation with hepatocytes and discuss potential inhibitors of hepatic maturation. In addition, we identified novel ncRNAs in the transcriptome of the analysed cells.

2. Materials and Method

2.1. Cell Culture. Induced pluripotent stem cells (iPSCs) were obtained from foreskin fibroblast by reprogramming with episomal vectors containing genes OCT4, SOX2, NANOG, KLF4, L-MYC, Lin28, and shRNA-p53 and the miR-302/367 cluster, along with the GFP marker (System Biosciences). Cells were cultured at 37°C in 5% CO2 in Essential 8 Medium (Life Technologies). Detailed description of the protocol for generation and characterization of the cells is described in [19]. Obtained iPSCs were split using Versene (Life Technologies) and seeded into Geltrex-coated (Life Technologies) six-well plates to initiate hepatic differentiation.

2.2. Hepatic Differentiation. Hepatic differentiation was performed following the protocol described in [20]. Briefly, when cells reach 70% confluence, the medium was changed for RPMI1640 media containing B27 Supplements Minus Insulin (Invitrogen), 100 ng/mL Activin A (R&D Systems), 20 ng/mL fibroblast growth factor 2 (FGF2) (R&D Systems), and 10 ng/mL bone morphogenetic protein 4 (BMP4) (PeproTech) to induce endoderm. After 8 days of culture, dishes were moved to hypoxia (4% O2) in RPMI/B27 Supplement (Invitrogen) medium with 20 ng/mL BMP4 and 10 ng/mL FGF2 for 5 days. Next, the medium was changed to RPMI/B27 supplemented with 20 ng/mL hepatocyte growth factor (HGF, PeproTech) for an additional 5 days in hypoxia. The final stage of differentiation was in HCM hepatocyte culture medium (Lonza, but omitting the EGF) supplemented with 20 ng/mL Oncostatin M (R&D Systems) for 5 days in normoxia (21% O2). During that time, the medium was freshly prepared and changed daily.

2.3. Immunofluorescence. Cells were fixed for 15 min at room temperature (RT) in 4% paraformaldehyde solution Roti-Histofix (Carl Roth GmbH & Co. KG), then washed three times in PBS (Life Technologies), and blocked and permeabilized for 1 hour in PBS with 1% fetal bovine serum (Sigma-Aldrich) and 0.1% of saponin (Sigma-Aldrich). Cells were then incubated with primary antibodies overnight at 4°C, rinsed with PBS, and incubated with secondary antibodies for 1 hour at RT. DAPI was used as a nuclear counterstain (Thermo Scientific). Antibodies used for characterization were alpha-fetoprotein (Dako A0008, rabbit polyclonal), HNF4a (Abcam ab92378, rabbit monoclonal), albumin (R&D Systems mab1455, mouse monoclonal), and cytokeratin-18 (Abcam ab82254, mouse monoclonal). To validate the efficiency, cells were cultured on two-well slides (Thermo Fisher Scientific Inc.) and after hepatic differentiation stained as described above for HNF4a and ALB. Whole slides (four wells in total) were scanned. The image analysis tool ImageJ (Schneider et al., 2012) was used to measure the area of double-positive cells.

2.4. qPCR. Gene expression of hepatocyte-specific proteins (protein phosphatase 1 (PP1), human hepatocyte nuclear factor 4 (HNF4a), albumin (ALB), alpha-fetoprotein (AFP), alpha-1 antitrypsin (A1AT)) was validated using qPCR. The total RNA was isolated from cells at day 24 using RNeasy Mini Kit (Qiagen). RNA was reverse transcribed according to the manufacturer’s protocol. Expression of the target mRNAs was quantified using Applied Biosystems 7500 Real-Time PCR System with SYBR Green PCR Master Mix. Each reaction was performed in triplicate under the following conditions: 95°C 5 min followed by 40 cycles of 95°C for 15 s denaturation, 60°C 15 s annealing, and 72°C for 30 s extension. To choose endogenous control, the expression of 10 genes was compared. The primers were purchased from BIOMOL (HHK-1). The protein phosphatase 1 (PP1) gene was used as endogenous control as a gene with the smallest variance between samples. The Ct value was normalized against the endogenous control to obtain ΔCt; we used the following formula for gene expression = 2^–ΔΔCt, where ΔΔCt = Ct (gene of interest average) – Ct (endogenous control average). The following primers were used: protein phosphatase 1 (PP1) F 5′-TTC ATC ATC TGC ACT GCC AAG AC-3′, R 5′-TCG AGT TGT CCA CAG TCA GC-3; human hepatocyte nuclear factor 4 (HNF4a) F 5′-ATG GCT CTC CTG AGA GTG GA-3′, R 5′-CAG CCC AGA ACC TAA TGA CA-3′; albumin (ALB) F 5′-GAA ACA
Figure 1: Characterization of hepatic-like cells (HLCs): (a) HLC morphology; (b) immunocytochemical detection of hepatic markers in HLCs HNF4α, ALB, AFP, MRP2, and CK18; (c) periodic acid-Schiff staining to detect glycogen storage in HLCs; (d) indocyanine green uptake and release in HLCs; green dye in cells indicate active take up of the dye and metabolism; representative images of three independent experiments.
2.5. Periodic Acid-Schiff (PAS) Staining. Cells at day 24 of differentiation were stained using periodic acid-Schiff (PAS-) staining system (Sigma-Aldrich) according to the manufacturer’s instruction. Nuclei were counterstained with haematoxylin.

2.6. Indocyanine Green Uptake and Release. Indocyanine green (ICG, Cardiogreen, Sigma-Aldrich) was dissolved in DMSO (Sigma-Aldrich) and then added to the medium for 1 h. The final concentration of the resulting ICG solution was 1 mg/mL. After incubation, the medium was exchanged and images representing ICG uptake were taken. After 6 h, the functional ability of hepatocytes to remove the dye was inspected.
2.7. RNA Isolation and Sequencing. Total RNA, including short RNAs, was purified from frozen hepatocytes (pooled 10 donors HMCS10, GIBCO) and cells harvested at two different time points: day 20 of hepatic differentiation (hepatoblast stage of HD) and day 24, the last day of differentiation, using the miRNeasy Micro Kit (Qiagen) and quantified by NanoDrop spectrophotometer. Total RNA was used in the small RNA protocol with the TruSeq™ Small RNA sample prep kit v2 (Illumina) according to the instructions of the manufacturer. The barcoded libraries were size restricted between 140 and 165 bp, purified, and quantified using the Library Quantification Kit Illumina/Universal (KAPA Biosystems) according to the instructions of the manufacturer. Sequencing was performed with an Illumina HiScanSQ sequencer at the sequencing core facility of the IZKF Leipzig (Faculty of Medicine, Leipzig University).

2.8. Computational Analysis. The raw reads were prepared (quality control, adapter trimming) for mapping to the human genome assembly hg38 with segemehl [21], allowing multiple read mapping. Afterwards, the mapped reads were overlapped with the gene annotation (GENCODE v24) and the RepeatMasker track (retrieved from UCSC 2016/10/20) using macounter (J. Delafontaine, bbcf.epfl.ch) and bedtools [22], respectively. Additionally, up-to-date human snoRNA annotations were taken from literature [23]. The genomic regions that show expression signals but remain without annotations were aggregated to loci. Reads that map within a distance of 120 nucleotides were merged. Loci with a minimum coverage of 10 reads and a minimal length of 20 nucleotides were considered as putative novel ncRNAs.

2.9. Identification of Novel ncRNA Candidates. For loci with expression signals in all samples (day 20, day 24, and hepatocytes), we aimed to identify the type of transcript. First, we removed loci overlapping with nuclear insertions of mitochondrial sequences (NuMTs). The NuMT track available for the human hg19 assembly at UCSC Table Browser was mapped to hg38 using liftOver and intersected with the loci. Then we applied tRNA scan [24], snoReport [25], and RNAz 2.0 [26] to identify tRNAs, novel snoRNA candidates, and further putative ncRNAs. For each locus, we checked the conservation by searching for homologous sequences in other deuterostomian species using blast [27] (E value: $10^{-31}$, minimal base identity: 50%, minimal score: 60, and minimal length of query: 50%). Found homologous sequences were used as queries in the subsequent blast search in the next species. We rejected repetitive loci (having more than 100 accepted blast hits in a species) from further comparative analysis. Alignments containing all found homologous sequences were computed with MUSCLE [28]. Consensus secondary structures were computed using RNAalifold [29] under RALEE mode [30] in Emacs. To detect snoRNA sequences that have not been identified with

![Figure 4: Correlation of gene expression levels between samples. Each pie chart represents the Pearson correlation (full pie chart and dark blue: correlation 1).](Image)
Figure 5: Detailed representation of expression changes of selected miRNAs in HLCs at days 20 and 24 of differentiation (d20 and d24, resp.) in comparison to hepatocytes: (a) hepatic-specific miRNAs (miR-122-5p, miR-27b-3p, miR-23b-3p, and miR-148-3p); miRNAs upregulated at day 24 of hepatic differentiation; (b) fetal liver-specific miRNAs (miR-23a-3p, miR-30a-5p, miR-483-3p, and miR-92b-3p); (c) miRNAs related to epithelial phenotype of HLCs (miR-200c-3p, miR-204, miR-429, and miR-199a-3p); (d) miRNAs connected to PI3K signaling (miR-21-5p, miR-21-3p, miR-214-3p, and miR-216a-5p).
snoReport, we first scanned the reads for putative box motifs using position weight matrices of the snoRNA boxes C, D, \( C' \), \( D' \), H, and ACA constructed from all annotated human snoRNAs. If a sequence harboured motifs C and D, or H and HACA in correct order and distance, we checked if the sequence is also able to fold into the typical snoRNA secondary structure using RNAfold. For sequences identified as putative snoRNAs in this manner, homologs were searched using the snoStrip pipeline [31].

2.10. Analysis of Differentially Expressed ncRNAs. Differentially expressed genes were identified using edgeR, a bioconductor software package [32] from replicated count data for every group pairwise comparison. Differentially expressed miRNAs and snoRNAs were selected by a false discovery rate (FDR) less than 0.001 and sorted by the adjusted fold change (including only log fold change higher than 2, \(|\log FC| > 2\).

2.11. Prediction of Target Genes and Pathways for Differentially Expressed miRNAs. In order to identify predicted targets of differentially expressed miRNAs, the DIANA mirPath tool V3.0 was used [33]. For every comparison, up to 50 significant miRNAs were analysed. DIANA-TarBase v7.0 was used to analyse gene interactions. Fisher’s exact test was applied for statistical pathway union meta-analysis.

3. Results

3.1. Differentiation of iPSCs into Hepatocytes. During differentiation, stem cell morphology gradually changed towards the polygonal shape of hepatocytes. After 22 days of differentiation, we could observe binucleated cells and accumulation of lipid droplets (Figure 1(a)). The obtained HLCs exhibited a hepatic characteristic, including expression of the hepatic marker proteins albumin (ALB), hepatic nuclear factor 4 (HNF4), \( \alpha \)-fetoprotein (AFP), multidrug resistance-associated protein 2 (MRP2), and cytokeratin-18 (CK18) (Figure 1(b)). Validation of HNF4, ALB, AFP, and alpha-1 antitrypsin (A1AT) with q-PCR resulted in clear expression signals (Figure 2). Further, the HLCs had the potential to store glycogen (PAS staining) (Figure 1(c)) and were also able to metabolise indocyanine green (ICG) (Figure 1(d))
both functions being specific to liver tissue, thus indicating successful differentiation. Efficiency of hepatic differentiation was evaluated using whole slide scanning. The area of cells double positive for HNF4 and ALB staining was measured using the image analysis tool ImageJ. We calculated that 30% of the total cell culture vessel was inhabited by cells positive for both hepatic markers (Figure 3).

3.2. RNA Analysis. RNASeq of the different samples resulted in between 8.3 M and 25.2 M reads, of which 73% to 80% were longer than 17 nucleotides after adapter clipping. Between 92% and 94% of the clipped reads could be mapped (Supplementary Figure 1A). Between 345k and 1.45M reads were mapped to miRNAs, while between 4.14M and 11.9M reads were mapped to snoRNAs (Supplementary Figure 1B). Other types of transcripts were sequenced including rRNA (between 6.5% and 16.5%), snRNAs, lincRNAs (about 1%), and protein coding (between 0.6% and 7%) (Supplementary Figure 2). To visualize the consistency between replicates and global changes between the studied samples, hierarchical clustering of all detected ncRNAs was performed (Figure 4). This revealed a strong separation between hepatocytes and hepatic-like cells and good homogeneity within each group.

3.3. MicroRNAs during Differentiation of iPSC Cells. We found about 20% (612/2812) of annotated miRNAs expressed (using a minimum of 10 reads as a cutoff) in at least one of the investigated samples. Hepatic-specific miR-122-5p, miR-27b-3p, miR-23b-3p, miR-148-3p, miR-146b-5p, and miR-194-5b were upregulated in hepatocytes. However, their expression in HLCs was decreased in comparison to hepatocytes (Figure 5). Nevertheless, elevated expression of mature hepatic miRNAs in HLC day 24 (d24) in comparison to HLC day 20 (d20) indicates hepatic lineage commitment during differentiation. The miRNAs upregulated in HLC day 24 in comparison to hepatocytes or HLC day 20 of differentiation have been reported to be specific for fetal hepatocytes: miR-23a-3p, miR-30a-5p, miR-483-3p, and miR-92b-3p. Upregulation of fetal liver miRNAs and expression of mature liver miRNAs in HLCs show that differentiated cells resemble a more fetal characteristic, which is in line with previous reports [7]. Remarkably, several miRNAs upregulated at the end of differentiation indicate an epithelial phenotype of HLCs. Those miRNAs which have previously been described as blocking epithelial to mesenchymal transition (EMT) were plotted separately: miR-200c-3p, miR-204-5p, miR-429, and miR-199a-3p. We also highlight miRNAs which have previously been shown to have increased expression levels during the last stage of hepatic differentiation of embryonic stem cells (ESCs) and are connected to P13K signaling and differentiation: miR-21-3p, miR-21-5p, miR-214, and miR-216a [34].

We identify differentially expressed miRNAs between control hepatocytes and the different stages of differentiation (day 20 and day 24). Those with adjusted low p values (FDR) and at the same time high fold changes are marked and visualized in volcano plots (Figure 6). As expected, the miRNA expression changed during hepatic differentiation. In brief, 14 differentially expressed miRNAs were identified when HLCs were compared at day 20 and at day 24 of differentiation. Five miRNAs were downregulated in HLCs at day 24 including miR-367, miR-302, and miR-516. Another 19 miRNAs were upregulated, most remarkably miR-199a, miR-199b, miR-211, and miR-214. When mature hepatocytes were compared to HLCs at day 24, 228 miRNAs emerged as downregulated in the mature liver cells. This list contains in particular miR-181d, miR-199a, miR-214, miR-200c, and miR-205. Another 88 miRNAs were upregulated in hepatocytes: let-7b-5p, miR-29c, let-7f-5p, let-7g-5p, miR-612, and miR-195 among others. Three quarters of the differentially expressed miRNAs in hepatocytes compared with HLCs at day 24 were also identified as differentially expressed in hepatocytes compared to HLCs at day 20. To visualize the differentially expressed miRNAs, a heat map was prepared (Figure 7). A complete list of differentially expressed miRNAs is provided in Supplementary Table 1.

We analysed the enrichment of the KEGG gene ontology terms of miRNA target genes related to differentially expressed miRNAs. The resulting pathways are presented in Table 1. Target genes of upregulated miRNAs in HLCs are involved in prion diseases, fatty acid biosynthesis and metabolism, proteoglycans in cancer, ECM-receptor interaction, adherens junction, viral carcinogenesis, Hippo signaling
| Comparison | KEGG pathway                          | p value       | #genes | #miRNAs |
|------------|---------------------------------------|---------------|--------|---------|
|            | Fatty acid biosynthesis                | 0             | 1      | 2       |
|            | ECM-receptor interaction               | 0             | 10     | 4       |
|            | Fatty acid metabolism                  | 5.984709e−10  | 2      | 2       |
| Upregulated miRNAs in HLC d24 compared to HLC d20 | Proteoglycans in cancer                | 2.928118e−09  | 31     | 3       |
|            | Hippo signaling pathway                | 0.0001180971  | 13     | 3       |
|            | Steroid biosynthesis                   | 0.004048092   | 2      | 2       |
|            | Adherens junction                      | 0.01782237    | 11     | 2       |
|            | Base excision repair                   | 0.02708153    | 4      | 2       |
|            | Lysine degradation                     | 1.389225e−08  | 9      | 2       |
|            | Chronic myeloid leukemia               | 0.0001602018  | 13     | 2       |
|            | Proteoglycans in cancer                | 0.0002270705  | 12     | 1       |
|            | Wnt signaling pathway                  | 0.0006146658  | 12     | 1       |
| Upregulated miRNAs in HLC d20 compared to HLC d24 | FoxO signaling pathway                 | 0.003220974   | 18     | 2       |
|            | Cell cycle                             | 0.003295535   | 9      | 1       |
|            | Pathways in cancer                     | 0.004235095   | 17     | 1       |
|            | Progesterone-mediated oocyte maturation| 0.03364343    | 8      | 1       |
|            | Oocyte meiosis                         | 0.03398087    | 5      | 1       |
|            | Signaling pathways regulating pluripotency of stem cells | 0.05899564 | 9 | 1 |
| Upregulated miRNAs in HLC d20 compared to hepatocytes | Fatty acid biosynthesis                | 0             | 4      | 4       |
|            | ECM-receptor interaction               | 0             | 29     | 10      |
|            | Lysine degradation                     | 0             | 26     | 17      |
|            | Proteoglycans in cancer                | 0             | 115    | 18      |
|            | MicroRNAs in cancer                    | 2.065015e−14  | 55     | 3       |
|            | Adherens junction                      | 1.92849e−10   | 56     | 14      |
| Upregulated miRNAs in HLC d20 compared to hepatocytes | Fatty acid metabolism                  | 2.435736e−07  | 12     | 5       |
|            | Hippo signaling pathway                | 2.854731e−07  | 76     | 15      |
|            | Prion diseases                         | 3.567319e−07  | 2      | 1       |
|            | Viral carcinogenesis                   | 4.563306e−07  | 90     | 10      |
|            | Pathways in cancer                     | 7.078609e−05  | 155    | 11      |
|            | Cell cycle                             | 0.0002485214  | 62     | 9       |
|            | p53 signaling pathway                  | 0.02762094    | 42     | 10      |
|            | Transcriptional misregulation in cancer| 0.02815897    | 70     | 8       |
| Upregulated miRNAs in hepatocytes compared to HLC d20 | Fatty acid biosynthesis                | 0             | 4      | 7       |
|            | ECM-receptor interaction               | 0             | 39     | 15      |
|            | Lysine degradation                     | 0             | 26     | 17      |
|            | Cell cycle                             | 0             | 92     | 17      |
|            | Viral carcinogenesis                   | 0             | 129    | 19      |
|            | Hippo signaling pathway                | 0             | 92     | 23      |
|            | Proteoglycans in cancer                | 0             | 140    | 23      |
|            | Pathways in cancer                     | 1.110223e−16  | 235    | 20      |
|            | Adherens junction                      | 8.881784e−16  | 59     | 20      |
|            | Hepatitis B                            | 3.774758e−15  | 83     | 13      |
|            | Chronic myeloid leukemia               | 3.940404e−12  | 54     | 18      |
|            | Colorectal cancer                      | 3.432521e−11  | 43     | 17      |
|            | Glioma                                 | 9.944934e−11  | 43     | 15      |
|            | Fatty acid metabolism                  | 1.771966e−06  | 14     | 8       |
|            | p53 signaling pathway                  | 2.456315e−06  | 47     | 16      |
|            | Small cell lung cancer                 | 8.452771e−06  | 57     | 14      |
| Comparison | KEGG pathway                            | \( p \) value | \#genes | \#miRNAs |
|------------|----------------------------------------|---------------|---------|---------|
|            | Oocyte meiosis                          | 1.56543e-05  | 65      | 12      |
|            | Thyroid hormone signaling pathway       | 2.996244e-05 | 64      | 11      |
|            | Steroid biosynthesis                    | 8.629469e-05 | 7       | 12      |
|            | Prostate cancer                         | 0.0004910115 | 65      | 13      |
|            | PI3K-Akt signaling pathway              | 0.001506451  | 118     | 10      |
|            | Focal adhesion                          | 0.001709285  | 81      | 9       |
|            | TGF-beta signaling pathway              | 0.004683835  | 48      | 9       |
|            | Prion diseases                          | 0            | 2       | 2       |
|            | Fatty acid biosynthesis                 | 0            | 4       | 6       |
|            | Fatty acid metabolism                   | 0            | 14      | 9       |
|            | Proteoglycans in cancer                 | 0            | 107     | 15      |
|            | ECM-receptor interaction                | 0            | 34      | 18      |
|            | Adherens junction                       | 2.136489e-10 | 52      | 16      |
|            | Viral carcinogenesis                    | 2.367215e-07 | 84      | 11      |
|            | Hippo signaling pathway                 | 8.686167e-05 | 76      | 14      |
|            | Pathways in cancer                      | 0.001098215  | 135     | 8       |
|            | Lysine degradation                      | 0.001337938  | 24      | 10      |
|            | Transcriptional misregulation in cancer | 0.003591186  | 53      | 7       |
|            | p53 signaling pathway                   | 0.04591601   | 39      | 11      |
| Upregulated miRNAs in HLC d24 compared to hepatocytes | | | | |
|            | Fatty acid biosynthesis                 | 0            | 4       | 7       |
|            | Hepatitis B                             | 0            | 91      | 15      |
|            | ECM-receptor interaction                | 0            | 41      | 16      |
|            | Lysine degradation                      | 0            | 27      | 18      |
|            | Cell cycle                              | 0            | 93      | 18      |
|            | Viral carcinogenesis                    | 0            | 132     | 18      |
|            | Pathways in cancer                      | 0            | 247     | 21      |
|            | Hippo signaling pathway                 | 0            | 91      | 22      |
|            | Proteoglycans in cancer                 | 0            | 143     | 23      |
|            | Adherens junction                       | 5.662137e-15 | 58      | 19      |
|            | Chronic myeloid leukemia                | 1.465494e-14 | 58      | 19      |
|            | Glioma                                  | 8.104628e-14 | 46      | 16      |
|            | Colorectal cancer                       | 8.277157e-12 | 45      | 18      |
|            | p53 signaling pathway                   | 2.698853e-08 | 47      | 17      |
|            | Oocyte meiosis                          | 1.888721e-07 | 67      | 13      |
|            | Small cell lung cancer                  | 5.78931e-07  | 61      | 15      |
|            | Thyroid hormone signaling pathway       | 1.055741e-05 | 64      | 11      |
|            | Prion diseases                          | 2.777397e-05 | 6       | 2       |
|            | Steroid biosynthesis                    | 4.649816e-05 | 10      | 11      |
|            | TGF-beta signaling pathway              | 6.111763e-05 | 52      | 11      |
|            | Prostate cancer                         | 0.0001155553 | 66      | 13      |
|            | Fatty acid metabolism                   | 0.0001381028 | 13      | 7       |
|            | PI3K-Akt signaling pathway              | 0.0001991286 | 138     | 11      |
|            | FoxO signaling pathway                   | 0.001107838  | 84      | 15      |
|            | Focal adhesion                          | 0.001779401  | 90      | 9       |
|            | Bladder cancer                          | 0.002833066  | 27      | 12      |
|            | Melanoma                                | 0.01182136   | 41      | 10      |
|            | Protein processing in endoplasmic reticulum | 0.01436954  | 105     | 12      |
|            | Endocytosis                             | 0.01445943   | 97      | 12      |
3.4. snoRNAs during Differentiation of iPSC Cells. We confirmed expression of 18 noncanonical SNORD-like (CD-box-like snoRNAs) and six candidate snoRNA genes reported in recent studies [23, 35]. These are expressed (minimum 10 reads) in at least one of the investigated samples. We identified many snoRNAs as differentially expressed between hepatocytes and HLCs at day 24 of differentiation.

3.5. Novel ncRNA Predictions. In expressed loci that do not overlap gene annotations, we were able to identify 23 novel ncRNA candidates. Most of the newly predicted RNA sequences are conserved during evolution. One CD box snoRNA could only be identified in human and three snoRNA families of each type are conserved also in other eutherian species. A list of all newly predicted ncRNA genes is provided in Table 2, and the conservation of novel genes is summarised in Supplementary Table 1.

3.6. snoRNA in Short Reads. In order to investigate whether analysis of snoRNA short reads (≈20 nt + adapter) alone gives
reasonable results for all snoRNA analysis (all snoRNA reads, full data set), we performed snoRNA differential expression analysis on short reads only. The results show that of differentially expressed snoRNAs from short reads (with an FDR of 0.001), 85 to 90% were also found differentially expressed in the full data set (containing about 4 times the number of snoRNA reads, mostly full length 50 nt). Of these still significantly different reads, only a maximum of 1% showed a different direction in change. This shows that miRNA sequencing, which usually gives snoRNA reads with adapters, can also be used to reliably investigate the differential expression of the snoRNAome (Figure 10).

4. Discussion

In this study, we analysed ncRNA profiles of iPSC-derived HLCs and compared them to profiles of hepatocytes to investigate potential inhibitors of hepatic maturation. The obtained HLCs express hepatic features; however, we could not attain high efficiency of differentiation. It was shown previously that hepatic differentiation efficiency varies between different protocols and depends on the used iPSC line [36]. The findings in this study are consistent with earlier data that HLCs differentiated from pluripotent stem cells have fetal characteristic [7].

We focused on comparison of miRNA profiles, which revealed that the gained HLCs undergo hepatic differentiation towards hepatic-like cells. Our results show upregulation of hepatic-specific miRNAs during the differentiation process in HLCs comparing day 20 with day 24. Additionally, the expression of fetal hepatic miRNAs was upregulated in HLCs especially on day 24 of differentiation when compared to hepatocytes. Analysis of differentially expressed miRNAs implicated that miRNAs whose expression is upregulated in HLCs are involved in differentiation, inhibition of proliferation, and maintenance of an epithelial phenotype.

Remarkably, analysis of differentially expressed miRNAs between HLCs at day 20 and day 24 showed that in HLCs at day 24, miR-199 is strongly upregulated, along with miR-214. Both miRNAs are regulators of skeleton formation, cardiogenesis, and cancer [37]. It has been shown that inhibition of miR-199a-5p improved hanging drop hepatic differentiation methods and liver repopulation ability of HLC derived from ESCs [38]. Furthermore, Möbus et al. also identified new target genes of miR-199a-5p, which are regulators of hepatocyte development. These findings might have important implications in the future when aiming to improve artificial hepatic maturation. miR-199a was also shown to be involved in liver fibrosis through deposition of extracellular matrix and profibrotic cytokine release, together with the miR-200 family [39, 40].

The miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) is known as epithelial markers which were linked to inhibition of EMT by repressing ZEB1, ZEB2, and Snail [41]. Expression of those miRNAs is elevated in HLCs and can indicate that hepatic maturation and EMT is
inhibited. During liver development, EMT is a natural process of hepatocyte differentiation, but it is also involved in carcinogenesis [42, 43]. Nevertheless, in a study of MSC-derived HLCs by Raut and Khanna (human umbilical cord Wharton’s jelly-derived MSCs), it has been reported that EMT-related miRNAs are upregulated in the last days of hepatic differentiation [34]. Potential EMT inhibition during differentiation should be resolved in follow-up studies.

The HLCs obtained in this study had higher expression levels of miRNAs associated with phosphatidylinositol-3-kinase (PI3K) (miR-21, miR-214, and miR-216a) when compared to hepatocytes, which has also been described by Kim et al. [44]. Analysis with DIANA mirPath showed that upregulated miRNAs from hepatocytes also control the PI3K signaling pathway. This suggests that this pathway might be maintained by different miRNAs during hepatocyte differentiation and in the mature state.

miR-181 is another miRNA whose expression is highly upregulated in HLCs. It has been found highly abundant in fetal liver and has been linked to hepatocarcinoma [45]. In cancer cells, expression of epithelial cell adhesion molecule (EpCAM) was related to high miR-181 levels. This miRNA, however, targets epithelial gene caudal-type homeobox transcription factor 2 (CDX2) which promotes EMT. This suggests that expression of miR-181 might be essential in the balance between the epithelial and mesenchymal phenotypes in hepatocytes.

An analysis of KEGG pathways related to differentially expressed miRNAs in hepatocytes revealed that they control several pathways: the PI3K signaling pathway, as mentioned above, as well as focal adhesion, the TGF-beta signaling pathway, and the thyroid hormone signaling pathway. It was shown that transient hypothyroidism increases expression of miR-1, miR-206, miR-133a, and miR-133b in liver cells [46]. Interestingly, miR-1-3p and miR-133a were also identified in the group of differentially expressed miRNAs from HLCs. Differentially expressed, enriched miRNAs from HLCs compared to hepatocytes control fatty acid biosynthesis and metabolism, ECM-receptor interaction, proteoglycans in cancer, Hippo signaling pathway, adherens junction, lysine degradation, prion diseases, viral carcinogenesis, pathways in cancer, p53 signaling pathway, and cell cycle. The HLCs obtained in this study have fetal character, and tissue remodelling processes take place as a result of differentiation process. This result shows again that obtained HLCs are immature and undergoing many metabolic changes. Many of the differentially expressed miRNAs in HLCs are also involved in cancer. To clarify the miRNA interplay with genes and molecules, additional research is needed. The hepatic differentiation process is still limited. However, expression profiles obtained in this study will be helpful to understand the mechanism of differentiation and indicate the way of future research.

Strong evidence of differentially expressed snoRNAs was found in our dataset. A very useful methodological result in this context is that differential expression of snoRNAs can be detected and quantified reliably from miRNA-seq data and does not require sequencing of RNAs in a size range geared towards detecting snoRNAs.

Many of the differentially expressed snoRNAs belong to imprinted loci. Previously, hepatic snoRNAs from these regions were compared with ten other human tissues by [15]. All of those imprinted genes had low expression levels in the liver. Our results show that SNORD113, SNORD114, and SNORD116 are downregulated in hepatocytes compared to HLCs, and members of SNORD115 are upregulated. This is in line with a study on the Prader-Willi syndrome locus where SNORD115 had higher expression levels than SNORD116 in the liver [47].

Finally, our data revealed 23 novel putative snoRNA families as well as four unclassified structured ncRNAs, most of which were evolutionarily young, suggesting that the repertoire of small structured RNAs is subject to rapid, lineage-specific expansions. For snoRNAs in particular, this points at functions beyond the ancient one as guide for chemical modification of ribosomal RNAs and snRNAs.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that there is no conflict of interest regarding the publication of this paper.
Authors’ Contributions

Shibashish Giri, Augustinus Bader, and Peter F. Stadler contributed equally to this work.

Acknowledgments

This work was supported by the EU Marie Skłodowska-Curie Actions ITN Project BIOART [Grant nos. 316690, EU-FP7-PEOPLE-ITN-2012].

Supplementary Materials

Figure 1: statistics of RNASeq. (A) Total number of sequenced reads, reads after clipping, and mapped reads; both symbolized all reads obtained after sequencing. The bar showing clipped reads contains reads that could be processed by cutting the helper sequences. Mapped read bar shows reads aligned to a reference genome. Clipped and mapped reads are divided into reads containing an adapter (length below 50 nt) and reads that do not contain an adapter (length ≥ 50 nt). (B) Percentage of mapped reads with an adapter; mapped reads of miRNA and snoRNA are divided into reads containing an adapter (length below 50 nt) and reads that do not contain an adapter (length ≥ 50 nt); HLCd20 and HLCd24 show reads from HLC day 20 and HLC day 24, respectively, of differentiation, in comparison to reads from hepatocytes. Figure 2: percentage of different transcript types in the sequencing; identified ncRNA without miRNA and snoRNA transcripts which were successfully mapped and overlapped genome annotations. HLCd20 and HLCd24 show transcripts from HLC day 20 and HLC day 24, respectively, of differentiation, in comparison to transcripts from hepatocytes. Table 1: list of differentially expressed miRNA and snoRNA. Table 2: conservation of snoRNA candidates. (Supplementary Materials)

References

[1] E. A. Kimbrel and R. Lanza, “Current status of pluripotent stem cells: moving the first therapies to the clinic,” Nature Reviews Drug Discovery, vol. 14, no. 10, pp. 681–692, 2015.
[2] H. Kamao, M. Mandai, S. Okamoto et al., “Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application,” Stem Cell Reports, vol. 2, no. 2, pp. 205–218, 2014.
[3] H. Malhi and G. J. Gores, “Cellular and molecular mechanisms of liver injury,” Gastroenterology, vol. 134, no. 6, pp. 1641–1654, 2008.
[4] E. Tsolaki and E. Yannaki, “Stem cell-based regenerative opportunities for the liver: state of the art and beyond,” World Journal of Gastroenterology, vol. 21, no. 43, article 12334, 12350 pages, 2015.
[5] M. Sgodda, S. Mobus, J. Hoepfner et al., “Improved hepatic differentiation strategies for human induced pluripotent stem cells,” Current Molecular Medicine, vol. 13, no. 5, pp. 842–855, 2013.
[6] D. Szkolnicka and D. C. Hay, “Concise review: advances in generating hepatocytes from pluripotent stem cells for translational medicine,” Stem Cells, vol. 34, no. 6, pp. 1421–1426, 2016.
[7] M. Baxter, S. Withey, S. Harrison et al., “Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes,” Journal of Hepatology, vol. 62, no. 3, pp. 581–589, 2015.
[8] D. Liu, J. Fan, W. Zeng, Y. Zhou, S. Ingvarsson, and H. Chen, “Quantitative analysis of miRNA expression in several developmental stages of human livers,” Hepatology Research, vol. 40, no. 8, pp. 813–822, 2010.
[9] R. Doddapaneni, Y. K. Chawla, A. Das, J. K. Kalra, S. Ghosh, and A. Chakraborti, “Overexpression of microRNA-122 enhances in vitro hepatic differentiation of fetal liver-derived stem/progenitor cells,” Journal of Cellular Biochemistry, vol. 114, no. 7, pp. 1575–1583, 2013.
[10] F. Dupuis-Sandoval, M. Poirier, and M. S. Scott, “The emerging landscape of small nucleolar RNAs in cell biology,” Wiley Interdisciplinary Reviews: RNA, vol. 6, no. 4, pp. 381–397, 2015.
[11] T. Kiss, “Small nucleolar RNAs: an abundant group of non-coding RNAs with diverse cellular functions,” Cell, vol. 109, no. 2, pp. 145–148, 2002.
[12] C. Ender, A. Krek, M. R. Friedländer et al., “A human snoRNA with microRNA-like functions,” Molecular Cell, vol. 32, no. 4, pp. 519–528, 2008.
[13] M. Brameier, A. Herwig, R. Reinhardt, L. Walter, and J. Gruber, “Human box C/D snoRNAs with miRNA-like functions: expanding the range of regulatory RNAs,” Nucleic Acids Research, vol. 39, no. 2, pp. 675–686, 2011.
[14] A. M. Burroughs, Y. Ando, M. L. de Hoon et al., “Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin,” RNA Biology, vol. 8, no. 1, pp. 158–177, 2011.
[15] J. C. Castle, C. D. Armour, M. Löwer et al., “Digital genome-wide ncRNA expression, including SnoRNAs, across 11 human tissues using polyA-neutral amplification,” PLoS One, vol. 5, no. 7, article e11779, 2010.
[16] L. Ho, G. Lange, W. Zhao et al., “Select small nucleolar RNAs in blood components as novel biomarkers for improved identification of comorbid traumatic brain injury and post-traumatic stress disorder in veterans of the conflicts in Afghanistan and Iraq,” Journal of Neurotrauma, vol. 13, no. 5, pp. 5131–5142, 2016.
[17] M. M. F. Steinbusch, Y. Fang, P. I. Milner et al., “Serum snoRNAs as biomarkers for joint ageing and post traumatic osteoarthritis,” Scientific Reports, vol. 7, no. 1, 2017.
[18] A. Skrzypczyk, S. Giri, and A. Bader, “Generation of induced pluripotent stem cell line from foreskin fibroblasts,” Stem Cell Research, vol. 17, no. 3, pp. 572–575, 2016.
[19] Y. Yu, H. Liu, Y. Ikeda et al., “Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies,” Stem Cell Research, vol. 9, no. 3, pp. 196–207, 2012.
[20] S. Hoffmann, C. Otto, S. Kurtz et al., “Fast mapping of short sequences with mismatches, insertions and deletions using index structures,” PLoS Computational Biology, vol. 5, no. 9, article e1000502, 2009.
[22] A. R. Quinlan, “BEDTools: the Swiss-army tool for genome feature analysis,” Current Protocols in Bioinformatics, vol. 47, no. 1, pp. 11.12.1–11.12.34, 2014.

[23] H. Jorjani, S. Kehr, D. J. Jedlinski et al., “An updated human snoRNAome,” Nucleic Acids Research, vol. 44, no. 11, pp. 5068–5082, 2016.

[24] P. Schattner, A. N. Brooks, and T. M. Lowe, “tRNAscan-SE, snoscan and snoGPS web servers for the detection of tRNAs and snoRNAs,” Nucleic Acids Research, vol. 33, Web Server, pp. W686–W689, 2005.

[25] J. Hertel, I. L. Hofacker, and P. F. Stadler, “SnoReport: computational identification of snoRNAs with unknown targets,” Bioinformatics, vol. 24, no. 2, pp. 158–164, 2008.

[26] A. R. Gruber, S. Finidei, S. Washietl, I. L. Hofacker, and P. F. Stadler, “RNA2.0: improved noncoding RNA detection,” Pacific Symposium on Biocomputing, pp. 69–79, 2010.

[27] S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman, “Basic local alignment search tool,” Journal of Molecular Biology, vol. 215, no. 3, pp. 403–410, 1990.

[28] R. C. Edgar, “MUSCLE: multiple sequence alignment with high accuracy and high throughput,” Nucleic Acids Research, vol. 32, no. 5, pp. 1792–1800, 2004.

[29] S. H. Bernhart, I. L. Hofacker, S. Will, A. R. Gruber, and P. F. Stadler, “RNAalifold: improved consensus structure prediction for RNA alignments,” BMC Bioinformatics, vol. 9, no. 1, pp. 1–12, 2008.

[30] S. Griffiths-Jones, “RALEE—RNA alignment editor in Emacs,” Bioinformatics, vol. 21, no. 2, pp. 257–259, 2005.

[31] S. Bartschat, S. Kehr, H. Tafer, P. F. Stadler, and J. Hertel, “snoStrip: a snoRNA annotation pipeline,” Bioinformatics, vol. 30, no. 1, pp. 115–116, 2013.

[32] M. D. Robinson, D. J. McCarthy, and G. K. Smyth, “edgeR: a bioconductor package for differential expression analysis of digital gene expression data,” Bioinformatics, vol. 26, no. 1, pp. 139–140, 2010.

[33] I. S. Vlachos, K. Zagganas, M. D. Paraskevopoulos et al., “DIANA-miRPath v3.0: deciphering microRNA function with experimental support,” Nucleic Acids Research, vol. 43, no. W1, pp. W460–W466, 2015.

[34] A. Raut and A. Khanna, “High-throughput sequencing to identify microRNA signatures during hepatic differentiation of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells,” Hepatology Research, vol. 47, no. 9, pp. 910–927, 2017.

[35] S. Kishore, A. R. Gruber, D. J. Jedlinski, A. P. Syed, H. Jorjani, and M. Zavolan, “Insights into snoRNA biogenesis and processing from PAR-CLIP of snoRNA core proteins and small RNA sequencing,” Genome Biology, vol. 14, no. 5, p. R45, 2013.

[36] M. Kajiwara, T. Aoi, K. Okita et al., “Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 31, pp. 12538–12543, 2012.

[37] S. Gu and W.-Y. Chan, “Flexible and versatile as a chameleon—sophisticated functions of microRNA-199a,” International Journal of Molecular Sciences, vol. 13, no. 7, pp. 8449–8466, 2012.

[38] S. Möbus, D. Yang, Q. Yuan et al., “MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells,” Journal of Hepatology, vol. 62, no. 1, pp. 101–110, 2015.